EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic Escherichia coli (UPEC)

Marlena M Westcott iD, Alexis E Morse, Gavin Troy, Maria Blevins, Thomas Wierzba, John W Sanders

Microbiology Spectrum · 05.03.2024 · 12 (3)

DOI: 10.1128/spectrum.03661-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 05.03.2024. Verfasst von Marlena M Westcott und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Uropathogenic Escherichia coli, Escherichia coli Infections, Urinary Tract Infections, Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense (DOD).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uropathogenic Escherichia coli (UPEC) is the primary causative agent of lower urinary tract infection (UTI). UTI presents a serious health risk and has considerable secondary implications including economic burden, recurring episodes, and overuse of antibiotics. A safe and effective vaccine would address this widespread health problem and emerging antibiotic resistance. Killed, whole-cell vaccines have shown limited efficacy to prevent recurrent UTI in human trials. We explored photochemical inactivation with psoralen drugs and UVA light (PUVA), which crosslinks nucleic acid, as an alternative to protein-damaging methods of inactivation to improve whole-cell UTI vaccines. Exposure of UPEC to the psoralen drug AMT and UVA light resulted in a killed but metabolically active (KBMA) state, as reported previously for other PUVA-inactivated bacteria. The immunogenicity of PUVA-UPEC as compared to formalin-inactivated UPEC was compared in mice. Both generated high UPEC-specific serum IgG titers after intramuscular delivery. However, using functional adherence as a measure of surface protein integrity, we found differences in the properties of PUVA- and formalin-inactivated UPEC. Adhesion mediated by Type-1 and P-fimbriae was severely compromised by formalin but was unaffected by PUVA, indicating that PUVA preserved the functional conformation of fimbrial proteins, which are targets of protective immune responses. In vitro assays indicated that although they retained metabolic activity, PUVA-UPEC lost virulence properties that could negatively impact vaccine safety. Our results imply the potential for PUVA to improve killed, whole-cell UTI vaccines by generating bacteria that more closely resemble their live, infectious counterparts relative to vaccines generated with protein-damaging methods. IMPORTANCE Lower urinary tract infection (UTI), caused primarily by uropathogenic Escherichia coli , represents a significant health burden, accounting for 7 million primary care and 1 million emergency room visits annually in the United States. Women and the elderly are especially susceptible and recurrent infection (rUTI) is common in those populations. Lower UTI can lead to life-threatening systemic infection. UTI burden is manifested by healthcare dollars spent (1.5 billion annually), quality of life impact, and resistant strains emerging from antibiotic overuse. A safe and effective vaccine to prevent rUTI would address a substantial healthcare issue. Vaccines comprised of inactivated uropathogenic bacteria have yielded encouraging results in clinical trials but improvements that enhance vaccine performance are needed. To that end, we focused on inactivation methodology and provided data to support photochemical inactivation, which targets nucleic acid, as a promising alternative to conventional protein-damaging inactivation methods to improve whole-cell UTI vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uropathogenic Escherichia coliEscherichia coli InfectionsUrinary Tract InfectionsVaccinesNucleic AcidsFurocoumarinsEscherichia coli ProteinsHumansFemaleAnimalsMiceAgedQuality of LifeNeoplasm Recurrence, LocalAnti-Bacterial AgentsFormaldehyde

Stichwörter der Autor:innen

AMTUPECUV lightformalinphotochemical inactivationpsoralenurinary tract infectionuropathogenic E. colivaccine

Substanzen

Anti-Bacterial AgentsVaccinesFormaldehydeNucleic AcidsFurocoumarinsEscherichia coli Proteins

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.
  • Department of Internal Medicine, Infectious Diseases Section, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA.

ORCID-Profile: Marlena M Westcott

Förderung

  • U.S. Department of Defense (DOD)

Zitieren

APA

Westcott, M. M., Morse, A. E., Troy, G., Blevins, M., Wierzba, T., & Sanders, J. W. (2024). Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic Escherichia coli (UPEC). Microbiology Spectrum, 12(3). https://doi.org/10.1128/spectrum.03661-23

Vancouver

Westcott MM, Morse AE, Troy G, Blevins M, Wierzba T, Sanders JW. Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic Escherichia coli (UPEC). Microbiology Spectrum. 2024;12(3). doi:10.1128/spectrum.03661-23

BibTeX
@article{Westcott2024,
  author = {Westcott, Marlena M and Morse, Alexis E and Troy, Gavin and Blevins, Maria and Wierzba, Thomas and Sanders, John W},
  title = {Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic Escherichia coli (UPEC)},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {3},
  doi = {10.1128/spectrum.03661-23}
}
Kostenlos starten →